Small molecule · Antagonist of Muscarinic acetylcholine receptor M3 (CHRM3) · developed by Mylan Ireland
ApprovedFDA, Nov 2018
1Registered trials
What is Revefenacin?
Revefenacin is a long-acting muscarinic antagonist that binds muscarinic receptors, with inhibition of the M3 receptor on airway smooth muscle causing bronchodilation. It is given by inhalation and is studied in COPD exacerbation.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Yupelri, GSK-1160724, TD-4208, YUPELRI
Drug type
Small molecule
Targets
Muscarinic acetylcholine receptor M3 (CHRM3)
Mechanism
Antagonist of Muscarinic acetylcholine receptor M3 (CHRM3)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.